BioMarin and Ascendis Settle Global Patent Disputes Over Yuviwel
On August 31, 2026, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reached a binding settlement with Ascendis Pharma A/S (NASDAQ:ASND), resolving all global patent disputes related to the drug Yuviwel. The agreement ends ongoing legal conflicts and intellectual property challenges between the two companies, including an ITC investigation. Under the terms of the deal, Ascendis will pay BioMarin a 20% royalty on U.S. net sales of Yuviwel retroactively from its initial commercial sale date. Additionally, BioMarin receives an 18% royalty for EU, Brazil, and South Korea sales through May 2030. The settlement also grants Ascendis full licensing rights to use BioMarin's patents related to Yuviwel across all current and potential indications. Ascendis expects over €500 million in operating cash flow by the end of 2026, with a long-term revenue target of €5 billion by 2030. The European Medicines Agency is still reviewing Yuviwel's Marketing Authorization Application for approval.
